CORRESP Filing
ZyVersa Therapeutics, Inc.
Date: Aug. 5, 2025 · CIK: 0001859007 · Accession: 0001641172-25-022236
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-288470
Letter
Re: ZyVersa Therapeutics, Inc.
ZyVersa Therapeutics, Inc.
N. Commerce Parkway, Suite 208
Weston, Florida 33326
(754) 231-1688
August 5, 2025
VIA EDGAR SUBMISSION
U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549
Registration Statement on Form S-1
SEC File No. 333-288470
Request for Acceleration
To whom it may concern:
Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, ZyVersa Therapeutics, Inc. (the " Company ") hereby requests that the effective date of the Company's Registration Statement on Form S-1 (File No. 333-288470) (the " Registration Statement ") be accelerated so that the Company's Registration Statement will become effective at 4:30 P.M., eastern time, on August 6, 2025, or as soon thereafter as is practicable, or at such other time thereafter as our counsel, Thompson Hine LLP, may request by telephone. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Thompson Hine LLP, by calling Faith L. Charles at (212) 908-3905.
Please feel free to direct any questions or comments concerning this request to Faith L. Charles of Thompson Hine LLP at (212) 908-3905.
ZYVERSA THERAPEUTICS, INC.
By: /s/ Stephen C. Glover
Name: Stephen C. Glover
Title: Chief Executive Officer
Cc: Faith L. Charles, Thompson Hine LLP
Show Raw Text
CORRESP 1 filename1.htm ZyVersa Therapeutics, Inc. 2200 N. Commerce Parkway, Suite 208 Weston, Florida 33326 (754) 231-1688 August 5, 2025 VIA EDGAR SUBMISSION U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: ZyVersa Therapeutics, Inc. Registration Statement on Form S-1 SEC File No. 333-288470 Request for Acceleration To whom it may concern: Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, ZyVersa Therapeutics, Inc. (the " Company ") hereby requests that the effective date of the Company's Registration Statement on Form S-1 (File No. 333-288470) (the " Registration Statement ") be accelerated so that the Company's Registration Statement will become effective at 4:30 P.M., eastern time, on August 6, 2025, or as soon thereafter as is practicable, or at such other time thereafter as our counsel, Thompson Hine LLP, may request by telephone. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Thompson Hine LLP, by calling Faith L. Charles at (212) 908-3905. Please feel free to direct any questions or comments concerning this request to Faith L. Charles of Thompson Hine LLP at (212) 908-3905. ZYVERSA THERAPEUTICS, INC. By: /s/ Stephen C. Glover Name: Stephen C. Glover Title: Chief Executive Officer Cc: Faith L. Charles, Thompson Hine LLP